Business, energy, technology, markets and global industry news from Business News Today

MonumenTAL-6

PharmaDeviceNews MonumenTAL-6
A Phase 3 multiple myeloma research setting reflects Johnson & Johnson’s MonumenTAL-6 study, in which the Tecvayli-Talvey combination reportedly reduced the risk of disease progression or death by 89%. Representative image.
Pharma & Biotech

MonumenTAL-6 trial strengthens Johnson & Johnson’s dual-target multiple myeloma strategy

Johnson & Johnson’s Tecvayli-Talvey regimen cut progression risk by 89% in MonumenTAL-6. See what the topline data still must prove.

Read More